Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis. Zheng Z, Zhu H, Fang L. PLoS One 2025;20:e0320189.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zheng Z, Zhu H, Fang L. Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis. PLoS One 2025;20:e0320189.
PMID: 40131983